Related references
Note: Only part of the references are listed.Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Carla Casulo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
B-cell targeted therapeutics in clinical development
Stephan Blueml et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases
Cornelis M. van Tilburg et al.
PEDIATRIC BLOOD & CANCER (2012)
Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
Nils Venhoff et al.
PLOS ONE (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
Y. L. Kasamon et al.
ANNALS OF ONCOLOGY (2010)
Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis
Erika Irie et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Does rituximab aggravate pre-existing hypogammaglobulinaemia?
Lavanya Diwakar et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma
Alison R. Walker et al.
CANCER INVESTIGATION (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation
Mitsufumi Nishio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Share Paper
